Overview

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to test the response of study participants' tumor to pembrolizumab alone, and in combination with axitinib, and to see what effects (good and bad) these drugs have on patients with advanced kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Oklahoma
Collaborators:
Merck Sharp & Dohme Corp.
Pfizer
Treatments:
Axitinib
Pembrolizumab